Immunocore Holdings (IMCR) Depreciation & Amortization (CF) (2021 - 2026)

Immunocore Holdings has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $948000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 11.01% year-over-year to $948000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 16.98% YoY) and the FY2025 annual result came in at $3.3 million, down 22.31% from the prior year.
• Depreciation & Amortization (CF) grew to $948000.0 in Q1 2026 per IMCR's latest filing, from $834000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.7 million in Q3 2022 and troughed at $780000.0 in Q2 2025.
• A 5-year average of $1.1 million and a median of $1.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) slumped 38.13% in 2023, then advanced 12.98% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.6 million in 2022, then sank by 34.19% to $1.0 million in 2023, then rose by 12.98% to $1.2 million in 2024, then declined by 28.47% to $834000.0 in 2025, then gained by 13.67% to $948000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $948000.0, $834000.0, and $798000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.